Vol. 5, Issue 2, Part A (2023)

In India, atherosclerotic heart disease is a primary cause of mortality and morbidity. Several hypolipidemic medications target low-density lipoprotein cholesterol (LDL-C) to reduce the risk of atherosclerosis. Statins remain the gold standard for dyslipidemia management. Despite the fact that lipid-lowering medicines, particularly statins, have demonstrated significant success in lowering the risk of cardiovascular disease (CVD), many patients fail to meet the lipid targets indicated by clinical recommendations. Bempedoic acid is a novel hypolipidemic agent that inhibits the adenosine triphosphate citrate lyase enzyme in the cholesterol production pathway. Results from the Cholesterol Lowering via Bempedoic Acid [ECT1002], an ACL-Inhibiting Regimen (CLEAR) trial have demonstrated that bempedoic acid added to maximally tolerated statin therapy provided long-term safety and efficacy. Bempedoic acid is a significant addition to the therapeutic options for individuals with high LDL-C. This article explores the perspectives of Indian experts on the role of bempedoic acid in lipid management.